This week several landmark announcements were made regarding the treatment of mesothelioma and Hepatitis C. The pharmaceutical industry is making great strides if treatment and cure.
Perhaps targeting the drug industry at this time merely to reduce costs is short sighted. The entire program needs to be encouraged.
US FDA: Designation for CRS-207 in Mesothelioma Treatment
Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
